Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non-small cell lung cancer

被引:51
|
作者
Rakaee, Mehrdad [1 ]
Kilvaer, Thomas K. [2 ,3 ]
Dalen, Stig Manfred [4 ]
Richardsen, Elin [1 ,4 ]
Paulsen, Erna-Elise [2 ,3 ]
Hald, Sigurd M. [3 ]
Al-Saad, Samer [1 ,4 ]
Andersen, Sigve [2 ,3 ]
Donnem, Tom [2 ,3 ]
Bremnes, Roy M. [2 ,3 ]
Busund, Lill-Tove [1 ,4 ]
机构
[1] UiT Arctic Univ Norway, Dept Med Biol, N-9019 Tromso, Norway
[2] Univ Hosp North Norway, Dept Oncol, N-9019 Tromso, Norway
[3] UiT Arctic Univ Norway, Dept Clin Med, N-9019 Tromso, Norway
[4] Univ Hosp North Norway, Dept Clin Pathol, N-9019 Tromso, Norway
关键词
TILs; Tumor-infiltrating lymphocytes; NSCLC; Prognosis; Lung cancer; Immunoscore; STAGE; RECOMMENDATIONS; CLASSIFICATION; IMMUNOSCORE; DENSITY; RECURRENCE; PROGNOSIS; MARKER; IMPACT; TILS;
D O I
10.1016/j.humpath.2018.05.017
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The presence of tumor-infiltrating lymphocytes (TILs) positively impacts the outcome of non- small cell lung cancer (NSCLC) patients. Most previous studies have assessed TILs using different immunohistochemical assays. The purpose of this study was to develop and validate a histopathological scoring model for the assessment of TILs in whole-tissue hematoxylin and eosin (H&E)-stained section slides of NSCLC patients and to evaluate the model in an immunoscore setting. Therefore, TIL was evaluated manually on H&E slides from 537 surgical specimens of primary resected stage I-III NSCLC patients. Using stromal TIL score as a stepwise discrete variable, increasing survival was seen with rising TIL level: disease-specific survival (DSS; P = .008), overall survival (P = .036) and disease-free survival (P = .006). Subgroup analysis revealed that high stromal TILs level was associated with superior DSS (P = .047) in patients with squamous cell carcinoma, but not in patients with adenocarcinoma. Multivariable analysis confirmed that high TIL levels independently predict improved prognosis for all endpoints in the overall cohort. In conclusion, high stromal TIL level is an independent favorable prognostic factor in stage NSCLC patients. The comprehensive histological evaluation conducted in this study may be helpful in streamlining TIL quantification for routine clinical use in a future NSCLC immunoscore setting. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:188 / 198
页数:11
相关论文
共 50 条
  • [1] Clinical significance of tumor-infiltrating lymphocytes investigated using routine H&E slides in small cell lung cancer
    Zhou, Guangrun
    Zheng, Jifang
    Chen, Zhiwei
    Hu, Dan
    Li, Suyu
    Zhuang, Wu
    He, Zhiyong
    Lin, Gen
    Wu, Biao
    Zhang, Wei
    Fang, Weimin
    Zheng, Fei
    Wang, Jiezhong
    Chen, Gang
    Chen, Mingqiu
    RADIATION ONCOLOGY, 2022, 17 (01)
  • [2] Prognostic impact of tumor-infiltrating lymphocytes and neutrophils in resected non-small cell carcinoma
    Ishikawa, Ryou
    Kadota, Kyuichi
    Ikeda, Toshihiro
    Yoshida, Chihiro
    Kimura, Nachino
    Ibuki, Emi
    Go, Tetsuhiko
    Yokomise, Hiroyasu
    Haba, Reiji
    HUMAN PATHOLOGY, 2022, 125 : 87 - 96
  • [3] The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer
    Bremnes, Roy M.
    Busund, Lill-Tove
    Kilvaer, Thomas L.
    Andersen, Sigve
    Richardsen, Elin
    Paulsen, Erna Elise
    Hald, Sigurd
    Khanehkenari, Mehrdad Rakaee
    Cooper, Wendy A.
    Kao, Steven C.
    Donnem, Tom
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (06) : 789 - 800
  • [4] Prognostic impact of tumor-infiltrating lymphocytes in non-small cell lung carcinomas
    Mlika, Mona
    Saidi, Ayoub
    Mejri, Nesrine
    Abdennadher, Mehdi
    Haddouchi, Chokri
    Labidi, Soumeya
    Khiari, Hyem
    Boussen, Hamouda
    Hsairi, Mohamed
    Mezni, Faouzi
    ASIAN CARDIOVASCULAR & THORACIC ANNALS, 2022, 30 (02) : 177 - 184
  • [5] Arrangement and Architecture of Tumor-Infiltrating Lymphocyte on H&E Slides Predict OS in Nivolumab Treated Non-Small Cell Lung Cancer
    Wang, X.
    Barrera, C.
    Bera, K.
    Lu, C.
    Feldman, M.
    Schalper, K.
    Rimm, D.
    Velcheti, V.
    Madabhushi, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S350 - S351
  • [6] Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer
    Feng, Wen
    Li, Yuan
    Shen, Lei
    Cai, Xu-Wei
    Zhu, Zheng-Fei
    Chang, Jian-Hua
    Xiang, Jia-Qing
    Zhang, Ya-Wei
    Chen, Hai-Quan
    Fu, Xiao-Long
    ONCOTARGET, 2016, 7 (06) : 7227 - 7240
  • [7] MANUFACTURE IMPROVEMENTS FOR TUMOR-INFILTRATING LYMPHOCYTES FROM HUMAN NON-SMALL CELL LUNG CANCER
    Zhou, Y.
    Noldner, P.
    Parrott, R. E.
    Antonia, S.
    Shaz, B.
    CYTOTHERAPY, 2023, 25 (06) : S209 - S210
  • [8] Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer
    Plaugher, Daniel R.
    Childress, Avery R.
    Gosser, Christian M.
    Esoe, Dave-Preston
    Naughton, Kassandra J.
    Hao, Zhonglin
    Brainson, Christine F.
    CANCER LETTERS, 2024, 605
  • [9] Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer
    Liu, Hui
    Zhang, Tiantuo
    Ye, Jin
    Li, Hongtao
    Huang, Jing
    Li, Xiaodong
    Wu, Benquan
    Huang, Xubing
    Hou, Jinghui
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012, 61 (10) : 1849 - 1856
  • [10] Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer
    Zeng, Dong-Qiang
    Yu, Yun-Fang
    Ou, Qi-Yun
    Li, Xiao-Yin
    Zhong, Ru-Zhi
    Xie, Chuan-Miao
    Hu, Qiu-Gen
    ONCOTARGET, 2016, 7 (12) : 13765 - 13781